Nexxa.ai | $4,400,000 | (Jul 22, 2025)
Litero AI | $800,000 | (Jul 22, 2025)
xLight Inc. | $40,000,000 | (Jul 22, 2025)
Portal Biotech
United Kingdom
- London
- 01/07/2025
- Series A
- $35,000,000
Proteins are at the heart of every biological process, yet today’s tools still leave major blind spots. At Portal Biotech, we're developing the first platform capable of sequencing entire proteins at the single-molecule level, replacing fragmented views with a complete picture. We want to empower scientists to understand proteins in depth and in real time, enabling faster drug discovery, more accurate diagnostics, and stronger pandemic readiness.
Portal Biotech was founded by DNA-sequencing veterans, leveraging machine-learning algorithms and building on decades of in-house expertise in nanopore technology. By analysing full-length protein molecules at the single-molecule level, our platform delivers rapid, real-time information on protein identity, abundance, and structure. Those insights open frontiers in drug discovery, diagnostics, and fundamental research, helping scientists and clinicians to better understand human health and disease.
We’re looking for sharp minds to help bring this vision to life.
- Industry Biotechnology Research
- Website https://www.portalbiotech.com/
- LinkedIn https://www.linkedin.com/company/portal-biotech/
Related People
Andrew HeronFounder
United Kingdom -
Oxford, England
I’m a scientist, technologist, investor and entrepreneur. I work at the intersection of engineering biology, single-molecule biosensing, and AI to develop novel platform technologies for measuring biology better.
With two decades focused on developing next-generation nanopore-based sequencing and biosensing technologies, my work has helped lay the foundation for some of the most transformative tools in genomics and molecular diagnostics. I’ve dedicated my career to developing scalable, real-world applications of single-molecule technologies, first in the realm of DNA and RNA, and now to unlock the proteome.
As CEO and co-founder of Portal Biotech, I have the privilege of leading an exceptional team building the world’s first platform for full-length, single-molecule protein sequencing. We're reimagining proteomics and metabolomics by building a versatile and accessible benchtop platform for comprehensive characterisation of proteins and metabolites. Our ultimate goal is to make protein sequencing as ubiquitous as genomic sequencing is today, with the aim of accelerating drug development and discovery pipelines, enabling faster and more accurate diagnostics, and enhancing global biosecurity and resilience to future biothreats.
Radical AI | $55,000,000 | (Jul 22, 2025)
LeadStory | $2,750,000 | (Jul 22, 2025)
Xelix | $160,000,000 | (Jul 22, 2025)
Toduba | $4,090,457 | (Jul 22, 2025)
Alix | $20,000,000 | (Jul 22, 2025)
Ovasave | $1,200,000 | (Jul 22, 2025)
Magentic | $5,500,000 | (Jul 22, 2025)
WattCarbon | Undisclosed Amount | (Jul 18, 2025)
Occupi | $3,000,000 | (Jul 18, 2025)